21.00SEK+6.92%Mkt Cap: 1.36B SEKP/E: 55.81Last update: 2026-05-13
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOU…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)55.81
P/E (Forward)43.94
PEG—
P/B4.92
P/S10.41
EV/EBITDA41.36
EV/Revenue9.66
EPS (TTM)0.37
EPS (Forward)0.47
Cash Flow & Leverage
FCF Yield0.63%
FCF Margin6.60%
Operating CF32.02M SEK
CapEx (TTM)12.52M SEK
Net Debt/EBITDA-3.20
Net Debt-97.92M SEK
Technical
SMA 5018.76 (+12.0%)
SMA 20020.88 (+0.6%)
Beta1.70
S&P 52W Chg24.23%
Avg Vol (30d)71.21K
Avg Vol (10d)53.28K
Technical Indicators
RSI (14)60.4
MACD0.4264
MACD Signal0.4292
MACD Hist.-0.0028
BB Upper21.01 SEK
BB Middle20.05 SEK
BB Lower19.08 SEK
BB Width9.59%
ATR (14)0.8536 SEK
Vol Ratio (20d)1.05x
52W Range
15.6438% of range29.80
52W High29.80 SEK
52W Low15.64 SEK
Profitability
Gross Margin89.85%
EBITDA Margin23.36%
Profit Margin18.22%
Oper. Margin15.78%
ROE8.65%
ROA6.22%
Revenue Growth3.50%
Earnings Growth22.10%
Balance Sheet
Debt/Equity0.27
Current Ratio7.65
Quick Ratio6.14
Book Value/Sh4.198 SEK
Cash/Share2.587 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 4, 2012
Ownership
Shares Out.66.06M
Float55.21M
Insiders18.22%
Institutions36.08%
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)32.67 SEK
Target Range27.00 SEK – 41.00 SEK
# Analysts3
Company
Market Cap1.36B SEK
Enterprise Value1.27B SEK
Revenue (TTM)131.09M SEK
Gross Profit115.85M SEK
Net Income (TTM)23.50M SEK
Revenue/Share1.988 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees36
Last Price21.00 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0002485979